Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know

What Happened?

A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as investors reacted to escalating uncertainty tied to the U.S.-Iran conflict and policy deadlines set by the Trump administration. Markets dislike unpredictability, and these fears were amplified, raising concerns of prolonged conflict and rising oil prices. This negative outlook reflected in consumer confidence, with the University of Michigan's sentiment index sliding to a three-month low.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Dental Equipment & Technology company Align Technology (NASDAQ:ALGN) fell 6.7%. Is now the time to buy Align Technology? Access our full analysis report here, it’s free.
• Medical Devices & Supplies - Imaging, Diagnostics company QuidelOrtho (NASDAQ:QDEL) fell 4.6%. Is now the time to buy QuidelOrtho? Access our full analysis report here, it’s free.
• Patient Monitoring company DexCom (NASDAQ:DXCM) fell 5.5%. Is now the time to buy DexCom? Access our full analysis report here, it’s free.
• Patient Monitoring company Insulet (NASDAQ:PODD) fell 3.7%. Is now the time to buy Insulet? Access our full analysis report here, it’s free.
• Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) fell 5.7%. Is now the time to buy Omnicell? Access our full analysis report here, it’s free.

Zooming In On Align Technology (ALGN)

Align Technology’s shares are somewhat volatile and have had 13 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 10 days ago when the stock gained 4.9% on the news that Barclays upgraded the stock to overweight from equalweight, setting a price target of $200. The investment bank noted that a recent decline in the company's stock price had improved its investment profile.

Align Technology is up 5.3% since the beginning of the year, but at $164.31 per share, it is still trading 20.7% below its 52-week high of $207.19 from July 2025. Despite the year-to-date gain, investors who bought $1,000 worth of Align Technology’s shares 5 years ago would now be looking at only $318.42.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.